Search Bar & Filters
Found 4 Actively Recruiting clinical trials
Actively Recruiting
This research aims to evaluate the safety and effectiveness of the FloStent, a medical device used for treating men experiencing symptoms of Benign Prostatic Hyperplasia BPH. The study compares the FloStent implant procedure to a sham procedure without deploying the device. It involves men aged 45 and older with symptomatic BPH to better understand how this device may impact urinary symptoms. Participants will undergo a flexible cystoscopy procedure. Those randomized to the treatment group will receive the FloStent implant during this procedure, while those in the control group will have the cystoscopy without the implant deployment, serving as a sham treatment. The study is randomized, double-blind, and includes parallel groups to compare outcomes over time. Throughout the study, participants will be assessed on changes in their International Prostate Symptom Score IPSS over 12 months. Researchers will monitor symptom improvements at 3, 6, and 12 months to evaluate response rates. Participants will complete study visits and follow the protocol to help researchers gather data on the devices safety and impact on urinary symptoms.
Actively Recruiting
Researchers are evaluating LBP-EC01, a recombinant bacteriophage cocktail, for treating acute uncomplicated urinary tract infection UTI caused by drug-resistant E. coli in females aged 18 to 75 years. This Phase 2 study includes an initial open-label lead-in with 30 patients to determine the best dosing regimen, followed by a larger blinded, randomized trial comparing LBP-EC01 plus antibiotic to placebo plus antibiotic in 288 patients who have an active UTI at the start of the study. The study consists of two parts. In Part 1, participants receive different dose regimens of LBP-EC01 administered intraurethrally on Days 1 and 2, combined with intravenous dosing and oral trimethoprimsulfamethoxazole TMPSMX from Days 1 to 3. Part 2 involves randomizing participants to receive either the selected LBP-EC01 dose regimen or placebo, both alongside oral TMPSMX, following the same dosing schedule. The study evaluates safety, tolerability, pharmacokinetics, and efficacy. Participants will provide urine, blood, and stool samples and attend scheduled visits for assessments. Researchers will measure LBP-EC01 levels in urine and blood, track clinical symptom resolution, and monitor microbiologic response up to Day 10 and maintenance of response up to 6 months. Safety and immunogenicity will also be monitored through adverse event reporting and laboratory tests during and after treatment.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of a new multivalent pneumococcal vaccine called PG4 in healthy infants. This vaccine is being compared to the currently used 20-valent pneumococcal conjugate vaccine 20vPnC. The study aims to see how well the new vaccine helps fight germs that cause pneumonia, meningitis, and ear infections, and whether it provides additional protection against pneumococcal disease compared to the existing vaccine. The study includes three groups of infants based on age and location. Group 1 involves about 3000 infants who are 2 months old and will receive either PG4 or 20vPnC shots into the left thigh muscle at 2, 4, 6, and 12 to 15 months of age. Groups 2 and 3, with smaller numbers of infants from outside the United States aged 2 to 6 months, will receive different schedules of PG4 or 20vPnC either intramuscularly or under the skin. Each infant will be randomly assigned to one of the vaccine types and administration methods. Participants will be involved in the study for about 12 to 19 months depending on their group. During this time, infants will attend six clinic visits and one phone call, where parents or guardians will be asked about any side effects experienced. Blood samples will be collected three times to measure the immune response through proteins that fight the pneumococcal disease germs. The study also monitors local and systemic reactions, adverse events, and serious adverse events following vaccination.